Clinical Adoption of mHealth Technology to Support Pediatric Cystic Fibrosis Care in Sweden: Qualitative Case Study
Meghan Longacre1, Stuart Grande1, Andreas Hager2
1The Dartmouth Institute for Health Policy and Clinical Practice, The Geisel School of Medicine at Dartmouth, Dartmouth College, Lebanon, NH, United States.
Insights
Co-producing mobile health (mHealth) technology with patients and clinicians improved pediatric cystic fibrosis (CF) care integration. This approach fostered adoption and enhanced self-management for chronic conditions.
Area of Science:
- Digital Health
- Pediatric Chronic Care
- Health Informatics
Background:
- Mobile health (mHealth) offers potential for improving pediatric chronic disease management and care coordination.
- Implementation barriers include insufficient clinical support and infrastructure for mHealth tools.
- Co-producing mHealth solutions with end-users can enhance clinical integration.
Purpose of the Study:
- To explore the development, adoption, and integration of a co-produced mHealth platform (Genia) for pediatric cystic fibrosis (CF) management in Sweden.
Main Methods:
- A qualitative case study approach examined the introduction and use of the Genia platform.
- Data from 2014-2017, including interviews and meeting notes, were analyzed.
- Iterative content analysis identified themes in the mHealth adoption process.
Main Results:
- Four themes facilitated Genia's clinical integration: cultural readiness for mHealth, weekly huddles for iteration, patient engagement via 'Genia Talk', and a co-design approach.
- These factors supported the successful adoption of the mHealth platform.
Conclusions:
- Quality improvement, relational coordination, user-centered design, and coproduction principles are key for integrating mHealth into pediatric CF care.
- These strategies can overcome barriers and optimize mHealth implementation in clinical settings.
Background:
Mobile health (mHealth) technologies have potential to improve self-management and care co-ordination of pediatric chronic diseases requiring complex care, such as cystic fibrosis (CF). Barriers to implementation include the lack of support and infrastructure to use mHealth in the clinical microsystem. Coproducing mHealth technology with patients, clinicians, and designers may increase the likelihood of successful integration into the clinical setting.
Objective:
This study explored the development, adoption, and integration of a new, co-produced mHealth platform (Genia) for the management of pediatric CF in Sweden.
Methods:
A retrospective, qualitative case study approach was used. The case was defined as the process of introducing and using Genia at the Pediatric Cystic Fibrosis Center at Skåne University Hospital in Lund, Sweden. Data sources included interviews, presentations, meeting notes, and other archival documents created between 2014 and 2017. To be included, data sources must have described or reflected upon the Genia adoption process. Iterative content analysis of data source materials was conducted by 2 qualitatively trained researchers to derive themes characterizing the mHealth clinical adoption process.
Results:
In total, 4 core themes characterized successful clinical integration of Genia in Lund: cultural readiness to use mHealth; use of weekly huddles to foster momentum and rapid iteration; engagement in incremental "Genia Talk" to motivate patient adoption; and co-design approach toward pediatric chronic care.
Conclusions:
Principles of quality improvement, relational co-ordination, user-centered design, and coproduction can facilitate the integration of mHealth technology into clinical care systems for pediatric CF care.
Related Concept Videos
05:56Implementation of Non-invasive Point of Care Transient Elastography for Evaluation of Liver Disease in Pediatric Populations with Cystic Fibrosis
11:20Phage Therapy Application to Counteract Pseudomonas aeruginosa Infection in Cystic Fibrosis Zebrafish Embryos
01:23Cystic Fibrosis: Pathogenesis
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
03:53Growing a Cystic Fibrosis-Relevant Polymicrobial Biofilm to Probe Community Phenotypes
07:38Design and Development of a Model to Study the Effect of Supplemental Oxygen on the Cystic Fibrosis Airway Microbiome
07:56Rectal Organoid Morphology Analysis (ROMA): A Diagnostic Assay in Cystic Fibrosis